147,095 members

Skip to content. | Skip to navigation

News

Pertuzumab after surgery for early breast cancer not cost effective, says NICE

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

Pertuzumab after surgery for early breast cancer not cost effective, says NICE

Women with a type of early breast cancer may not benefit from continuing or starting a drug after having surgery, NICE says in draft guidance.

NICE already recommends pertuzumab (also called Perjeta and made by Roche), given with trastuzumab and chemotherapy, for treating early HER2-positive breast cancer before surgery. NICE also recommends it for treating HER2-positive breast cancer that has either recurred in the breast following initial treatment or has spread from the breast to elsewhere in the body.

NICE has now published draft guidance which does not recommend pertuzumab for women with HER2 positive early breast cancer who have a high risk of the disease recurring.